Clinical Effects of Liraglutide in a Real-World Setting in Spain : eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
INTRODUCTION: A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting.
METHODS: In a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor).
RESULTS: Mean baseline glycated hemoglobin (HbA1c) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/m(2). After 3-6 months of treatment with liraglutide, we observed a change in HbA1c of -1.1 ± 1.2%, -4.6 ± 5.3 kg in weight and -1.7 ± 2.0 kg/m(2) in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (-5.9 mmHg, p < 0.001), diastolic blood pressure (-3.2 mmHg, p < 0.001), LDL cholesterol (-0.189 mmol/l, p < 0.001) and triglycerides (-0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of -1.0% in HbA1c (p < 0.001) and a reduction in weight (-4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of -1.08% in HbA1c (p < 0.001) and a weight reduction of -4.15 kg (p < 0.001) were observed.
CONCLUSION: Our study confirms the effectiveness of liraglutide in a real-life and clinical practice setting.
FUNDING: Spanish Society of Endocrinology and Nutrition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Diabetes therapy : research, treatment and education of diabetes and related disorders - 6(2015), 2 vom: 01. Juni, Seite 173-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mezquita-Raya, Pedro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.06.2015 Date Revised 10.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s13300-015-0112-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249772450 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249772450 | ||
| 003 | DE-627 | ||
| 005 | 20231226192011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13300-015-0112-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0832.xml |
| 035 | |a (DE-627)NLM249772450 | ||
| 035 | |a (NLM)26055216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mezquita-Raya, Pedro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Effects of Liraglutide in a Real-World Setting in Spain |b eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2015 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting | ||
| 520 | |a METHODS: In a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor) | ||
| 520 | |a RESULTS: Mean baseline glycated hemoglobin (HbA1c) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/m(2). After 3-6 months of treatment with liraglutide, we observed a change in HbA1c of -1.1 ± 1.2%, -4.6 ± 5.3 kg in weight and -1.7 ± 2.0 kg/m(2) in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (-5.9 mmHg, p < 0.001), diastolic blood pressure (-3.2 mmHg, p < 0.001), LDL cholesterol (-0.189 mmol/l, p < 0.001) and triglycerides (-0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of -1.0% in HbA1c (p < 0.001) and a reduction in weight (-4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of -1.08% in HbA1c (p < 0.001) and a weight reduction of -4.15 kg (p < 0.001) were observed | ||
| 520 | |a CONCLUSION: Our study confirms the effectiveness of liraglutide in a real-life and clinical practice setting | ||
| 520 | |a FUNDING: Spanish Society of Endocrinology and Nutrition | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Reyes-Garcia, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Perez, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Escalada-San Martin, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Ángel Rubio Herrera, Miquel |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez de la Torre Casares, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes therapy : research, treatment and education of diabetes and related disorders |d 2012 |g 6(2015), 2 vom: 01. Juni, Seite 173-85 |w (DE-627)NLM215796888 |x 1869-6953 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2015 |g number:2 |g day:01 |g month:06 |g pages:173-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13300-015-0112-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2015 |e 2 |b 01 |c 06 |h 173-85 | ||